FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2010486222> ?p ?o ?g. }

• W2010486222 endingPage "106" @default.
• W2010486222 startingPage "97" @default.
• W2010486222 abstract "Bisphosphonates (BPs) used as inhibitors of bone resorption all contain two phosphonate groups attached to a single carbon atom, forming a P-C-P structure. The bisphosphonates are therefore stable analogues of naturally occuring pyrophosphate-containing compounds, which now helps to explain their intracellular as well as their extracellular modes of action. Bisphosphonates adsorb to bone mineral and inhibit bone resorption. The mode of action of bisphosphonates was originally ascribed to physico-chemical effects on hydroxyapatite crystals, but it has gradually become clear that cellular effects must also be involved. The marked structure-activity relationships observed among more complex compounds indicate that the pharmacophore required for maximal activity not only depends upon the bisphosphonate moiety but also on key features, e.g., nitrogen substitution in alkyl or heterocyclic side chains. Several bisphosphonates (e.g., etidronate, clodronate, pamidronate, alendronate, tiludronate, risedronate, and ibandronate) are established as effective treatments in clinical disorders such as Paget's disease of bone, myeloma, and bone metastases. Bisphosphonates are also now well established as successful antiresorptive agents for the prevention and treatment of osteoporosis. In particular, etidronate and alendronate are approved as therapies in many countries, and both can increase bone mass and produce a reduction in fracture rates to approximately half of control rates at the spine, hip, and other sites in postmenopausal women. In addition to inhibition of osteoclasts, the ability of bisphosphonates to reduce the activation frequency and birth rates of new bone remodeling units, and possibly to enhance osteon mineralisation, may also contribute to the reduction in fractures. The clinical pharmacology of bisphosphonates is characterized by low intestinal absorption, but highly selective localization and retention in bone. Significant side effects are minimal. Current issues with bisphosphonates include the introduction of new compounds, the choice of therapeutic regimen (e.g., the use of intermittent dosing rather than continuous), intravenous vs. oral therapy, the optimal duration of therapy, the combination with other drugs, and extension of their use to other conditions, including steroid-associated osteoporosis, male osteoporosis, arthritis, and osteopenic disorders in childhood. Bisphosphonates inhibit bone resorption by being selectively taken up and adsorbed to mineral surfaces in bone, where they interfere with the action of osteoclasts. It is likely that bisphosphonates are internalized by osteoclasts and interfere with specific biochemical processes and induce apoptosis. The molecular mechanisms by which these effects are brought about are becoming clearer. Recent studies show that bisphosphonates can be classified into at least two groups with different modes of action. Bisphosphonates that closely resemble pyrophosphate (such as clodronate and etidronate) can be metabolically incorporated into nonhydrolysable analogues of ATP that may inhibit ATP-dependent intracellular enzymes. The more potent, nitrogen-containing bisphosphonates (such as pamidronate, alendronate, risedronate, and ibandronate) are not metabolized in this way but can inhibit enzymes of the mevalonate pathway, thereby preventing the biosynthesis of isoprenoid compounds that are essential for the posttranslational modification of small GTPases. The inhibition of protein prenylation and the disruption of the function of these key regulatory proteins explains the loss of osteoclast activity and induction of apoptosis. These different modes of action might account for subtle differences between compounds in terms of their clinical effects. In conclusion, bisphosphonates are now established as an important class of drugs for the treatment of bone diseases, and their mode of action is being unravelled. As a result, their full therapeutic potential is gradual" @default.
• W2010486222 created "2016-06-24" @default.
• W2010486222 creator A5068713744 @default.
• W2010486222 creator A5081312172 @default.
• W2010486222 date "1999-07-01" @default.
• W2010486222 modified "2023-10-07" @default.
• W2010486222 title "Bisphosphonates: from the laboratory to the clinic and back again" @default.
• W2010486222 cites W125879246 @default.
• W2010486222 cites W1530002712 @default.
• W2010486222 cites W1873492158 @default.
• W2010486222 cites W1899517398 @default.
• W2010486222 cites W1968418396 @default.
• W2010486222 cites W1970270213 @default.
• W2010486222 cites W1971470705 @default.
• W2010486222 cites W1974903174 @default.
• W2010486222 cites W1975107690 @default.
• W2010486222 cites W1981084939 @default.
• W2010486222 cites W1984131196 @default.
• W2010486222 cites W1991208655 @default.
• W2010486222 cites W1993701679 @default.
• W2010486222 cites W1994414479 @default.
• W2010486222 cites W1996593783 @default.
• W2010486222 cites W1998709588 @default.
• W2010486222 cites W1998924309 @default.
• W2010486222 cites W1999347849 @default.
• W2010486222 cites W2004672175 @default.
• W2010486222 cites W2006848294 @default.
• W2010486222 cites W2007457073 @default.
• W2010486222 cites W2007569697 @default.
• W2010486222 cites W2007660746 @default.
• W2010486222 cites W2018777439 @default.
• W2010486222 cites W2023781848 @default.
• W2010486222 cites W2023787395 @default.
• W2010486222 cites W2024479120 @default.
• W2010486222 cites W2025917757 @default.
• W2010486222 cites W2029326044 @default.
• W2010486222 cites W2030989965 @default.
• W2010486222 cites W2031582882 @default.
• W2010486222 cites W2031851347 @default.
• W2010486222 cites W2033294313 @default.
• W2010486222 cites W2034913902 @default.
• W2010486222 cites W2035212880 @default.
• W2010486222 cites W2035373485 @default.
• W2010486222 cites W2037935981 @default.
• W2010486222 cites W2043175126 @default.
• W2010486222 cites W2044868144 @default.
• W2010486222 cites W2045747724 @default.
• W2010486222 cites W2045910004 @default.
• W2010486222 cites W2053201692 @default.
• W2010486222 cites W2057973214 @default.
• W2010486222 cites W2058580752 @default.
• W2010486222 cites W2060736857 @default.
• W2010486222 cites W2061235833 @default.
• W2010486222 cites W2063068824 @default.
• W2010486222 cites W2063084132 @default.
• W2010486222 cites W2070075606 @default.
• W2010486222 cites W2070191846 @default.
• W2010486222 cites W2070333621 @default.
• W2010486222 cites W2072986613 @default.
• W2010486222 cites W2073024058 @default.
• W2010486222 cites W2081588688 @default.
• W2010486222 cites W2089566066 @default.
• W2010486222 cites W2090232052 @default.
• W2010486222 cites W2093164779 @default.
• W2010486222 cites W2093226717 @default.
• W2010486222 cites W2096791952 @default.
• W2010486222 cites W2101719588 @default.
• W2010486222 cites W2102050391 @default.
• W2010486222 cites W2106142458 @default.
• W2010486222 cites W2109529667 @default.
• W2010486222 cites W2111748919 @default.
• W2010486222 cites W2114190206 @default.
• W2010486222 cites W2142229422 @default.
• W2010486222 cites W2153009489 @default.
• W2010486222 cites W2155728216 @default.
• W2010486222 cites W2161690532 @default.
• W2010486222 cites W2168222534 @default.
• W2010486222 cites W2176744910 @default.
• W2010486222 cites W2314428698 @default.
• W2010486222 cites W2314674563 @default.
• W2010486222 cites W2321227665 @default.
• W2010486222 cites W2321961720 @default.
• W2010486222 cites W2325284371 @default.
• W2010486222 cites W2325302070 @default.
• W2010486222 cites W2326201416 @default.
• W2010486222 cites W2329575366 @default.
• W2010486222 cites W2335475908 @default.
• W2010486222 cites W2336517627 @default.
• W2010486222 cites W2336678594 @default.
• W2010486222 cites W2346551411 @default.
• W2010486222 cites W4248150544 @default.
• W2010486222 cites W4250407548 @default.
• W2010486222 cites W4252019758 @default.
• W2010486222 doi "https://doi.org/10.1016/s8756-3282(99)00116-7" @default.
• W2010486222 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10423031" @default.
• W2010486222 hasPublicationYear "1999" @default.
• W2010486222 type Work @default.
• W2010486222 sameAs 2010486222 @default.

• next